For immediate release Fina Biosolutions founder Dr. Andrew Lees is the star of a video now playing on The Scientists’ Channel. In an exclusive interview, Lees, now the company’s CEO…
Development of FinaBio’s CRM197, EcoCRM® and Ready-to-ConjugateTM carrier proteins. Presented April 15, 2020 to the Canadian Glycomics Network About the Canadian Glycomics Network In 2015, the Canadian glycomics research community mobilized to…
Andrew Lees, Fina Biosolutions’ scientific director, speaks on the challenges of purifying conjugate vaccines and vaccine components. Ion Exchange: Pore choices and ion clouds: aspects of resin architecture that affect…
Meet with Fina Biosolutions through the BIO One-on-One Partnering at BIO2018. Fina Biosolutions will be at BIO 2018 in Boston June 4-7 2018. We will have a stand in the…
On February 1, 2018, Andrew Lees spoke at the Keystone meeting, Emerging Technologies in Vaccine Discovery and Development, held in Banff, Alberta, Canada. He chaired the session, “New Tools in…
Dr. Lees will discuss the challenges of developing and manufacturing affordable conjugate vaccines. He will review how efficient conjugation chemistry and affordable carrier protein can help reduce manufacturing costs.